NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
Bristol-Myers Squibb
Pfizer
Matrix Biomed, Inc.
Bayer
Leo W. Jenkins Cancer Center
University of Pennsylvania